Are Orphan Drugs Getting Too Much Attention By Payers And Policymakers?

Success of the Orphan Drug Act has brought with it pushback from payers, policymakers, and legislators. Pushback may be warranted in some instances. But, a case-by-case approach examining the value of orphan products, independent of their orphan status, is a more appropriate general policy.

Read the full post on Forbes - Pharma & Healthcare